Press releases

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that Janssen Pharmaceuticals Inc. (Janssen) has decided to terminate the license...

Press release 2017/11/10

Medivir appoints Christina Herder as Executive Vice President Strategic Business Development

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces today the appointment of Christina Herder, as Executive Vice President, Strategic Business...

Press release 2017/11/09

MIV-711 phase IIa osteoarthritis study data presented as a late breaking poster at the Annual Meeting of the American College for Rheumatology

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces that data from the initial phase IIa study of MIV-711 in patients...

Press release 2017/11/08

Medivir Announces New Cancer Project, Leukotide, derived from its in-house Nucleotide Platform

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces a new discovery project for a cancer indication. The Leukotide project...

Press release 2017/11/03 Regulatory

Medivir appoints Erik Björk as Chief Financial Officer

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces today that it has appointed Erik Björk as Chief Financial Officer effective...

Press release 2017/10/26 Regulatory

MEDIVIR AB – INTERIM REPORT, JANUARY – SEPTEMBER 2017

July - September Significant events during the quarter Positive topline results from phase IIa osteoarthritis study showed disease-modifying benefit and an...

Press release 2017/10/24 Regulatory

Medivir receives FDA Fast Track Designation for MIV-711 for the treatment of OA

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast...

Press release 2017/10/23

Data on the clinical activity of simeprevir in combination with AL-335 and odalasvir (JNJ-4178) presented at the 2017 Liver Meeting™

Stockholm, Sweden - Medivir AB (Nasdaq Stockholm: MVIR) today communicates phase IIb data on JNJ-4178, the triple combination consisting of simeprevir,...

Press release 2017/10/20

MIV-711 phase IIa osteoarthritis study data selected as late breaking abstract at the Annual Meeting of the American College for Rheumatology

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces that data from the initial phase IIa study of MIV-711 in patients...

Press release 2017/10/13 Regulatory

Remetinostat phase II data demonstrate efficacy on skin lesions, reduction of itching and high tolerability in patients with early-stage MF-type CTCL

Stockholm, Sweden - Medivir AB (Nasdaq Stockholm: MVIR) today announces that phase II efficacy and safety data in patients with Mycosis...

Press release 2017/10/05

AMR Centre deal with Medivir targets superbug time-bomb

Stockholm, Sweden and Alderley Park, England - Medivir AB (Nasdaq Stockholm: MVIR) and AMR Centre Ltd (AMRC) today announce signing of...

Press release 2017/09/25 Regulatory

Medivir announces positive topline results from phase IIa osteoarthritis study, showing disease-modifying benefit of MIV-711 on joint structure

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces positive top line data from MIV-711-201, the 6-month initial phase IIa...